RMD Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
1.5B
+2.3%
1.4B
+0.6%
1.4B
+6.5%
1.3B
-0.9%
1.3B
Cost of Revenue
594.1M
+11.6%
532.6M
-0.7%
536.3M
+5.8%
506.9M
-2.2%
518.6M
Gross Profit
869.5M
-3.3%
898.8M
+1.4%
886.5M
+7.0%
828.6M
-0.1%
829.4M
Operating Expenses
420.8M
+5.5%
399.0M
+1.1%
394.9M
+3.3%
382.1M
+1.9%
374.9M
R&D
105.7M
+12.2%
94.3M
+3.6%
91.0M
+4.2%
87.3M
+1.0%
86.4M
SG&A
296.3M
+3.7%
285.7M
+2.6%
278.4M
+7.4%
259.2M
-3.0%
267.2M
Operating Income
448.7M
-10.2%
499.8M
+1.7%
491.7M
+10.1%
446.5M
-1.8%
454.5M
EBITDA
493.5M
-11.7%
558.8M
+2.1%
547.5M
+7.3%
510.0M
-1.6%
518.2M
Net Income
383.4M
-3.8%
398.7M
+1.6%
392.6M
+12.6%
348.5M
-8.2%
379.7M
EPS (Basic)
$2.65
-3.3%
$2.74
+1.9%
$2.69
+13.0%
$2.38
-8.1%
$2.59
EPS (Diluted)
$2.64
-3.6%
$2.74
+2.2%
$2.68
+13.1%
$2.37
-8.1%
$2.58
Shares (Diluted)
145.2M
-0.3%
145.7M
-0.4%
146.4M
-0.4%
146.9M
-0.1%
147.1M
ResMed (RMD) โ€” Financials